Bone, joint, and mobility is the main area connected here, and any felt benefit should be read together with the human evidence base.
The 54.4 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the C tier remains conservative.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Bone and joint health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Immune and respiratory health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This range includes studies in specific patient groups. It is not a general dose or recommendation.
Standalone side-effect signals and combination cautions are listed separately.
The group showed a positive signal, but individual contributions are hard to isolate. Not a stack recommendation.
Paper IDs and full lists are private. Only study types and summaries are shown.
Compared with placebo, glucosamine, chondroitin, and their combination do not reduce joint pain or have an impact on narrowing of joint space and health authorities and health insurers should not cover the costs.
A systematic review and meta-analysis of all available randomized, controlled trials to determine the effects of chondroitin on pain and joint space width and to explore whether reported beneficial effects could be explained by biases affecting individual tria
There was evidence that glucosamine sulphate shows some clinical effectiveness in the treatment of OA of the knee and the proposal that the active substance may be sulphate should be explored further.
CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile.
Over 2 years, no treatment achieved a clinically important difference in WOMAC pain or function as compared with placebo, however, glucosamine and celecoxib showed beneficial but not significant trends.
Clinical trial evidence for the efficacy and safety of several specific approaches – acupuncture, manipulation, massage therapy, relaxation techniques including meditation, selected natural product supplements, and yoga – as used to manage chronic pain and rel